| Name | Title | Contact Details |
|---|
Faith Health Care is a licensed home health agency that provides exceptional quality home health care, multi-disease management, and transitional care services. They are Medicare and Medicaid certified and CHAP accredited.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Main Street Health Recovery is a Thornhill, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Best Place to be Your Best What is it that makes Baptist Health South Florida distinctive and unique among other healthcare organizations? Quite simply, it`s our commitment to putting quality first in everything we do. Everything we do at Baptist Health South Florida, we do to the best of our ability. That includes supporting our team with extensive training programs, millions of dollars in tuition assistance, comprehensive benefits and more. Baptist Health South Florida is the largest faith-based, not-for-profit health care organization in the region. Its network of services, supported by more than 23,000 employees, extends throughout Miami-Dade, Broward, Palm Beach and Monroe Counties. Our facilities include Baptist Hospital, Baptist Children`s Hospital, Bethesda Hospital East & West, Boca Raton Regional Hospital, Doctors Hospital, Fishermen`s Community Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital, West Kendall Baptist Hospital, and the Miami Cancer Institute; outpatient diagnostic and surgical facilities, such as our Baptist Medical Plazas and home health care services in the region. The Miami Cancer Institute and proton therapy center will usher in a new era of innovative, precision cancer treatment that is unmatched in South Florida today. Our not-for-profit facility is on track to bring nationally renowned oncology experts to what will become a world-class destination for patients from across the U.S., the Caribbean and Latin America. Our International Center of Miami is one of the largest hospital-based international programs in America. Thousands of people each year travel to Miami from around the world to visit our respected physicians and our medical facilities.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.